Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01931787 · ClinicalTrials.gov registry record · Phase 1
CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
A Phase 1 study of Recurrent Small Cell Lung Cancer, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT01931787: Completed Phase 1 study of Recurrent Small Cell Lung Cancer, sponsored by Wake Forest University Health Sciences.
NCT01931787 is a Phase 1 study of Recurrent Small Cell Lung Cancer that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 15 participants, below the 56-participant average among 5 other Recurrent Small Cell Lung Cancer trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01931787, a Phase 1 study of Recurrent Small Cell Lung Cancer, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot clinical trial studies CPI-613 (6,8-bis\[benzylthio\]octanoic acid) in treating patients with relapsed or refractory small cell lung cancer. CPI-613 may interfere with the growth of tumor cells and may be an effective treatment for small cell lung cancer.
Primary Outcome
The proportion of responders as the percent of patients who are SD, PR and CR will be estimated, as well as RR (sum of PR + CR) and disease control rate (DCR, which is the sum of SD, PR and CR). 95% confidence intervals will be included.
Conditions Studied
Interventions
- DRUG 6,8-bis(benzylthio)octanoic acid
Study Locations (1)
North Carolina
- Comprehensive Cancer Center of Wake Forest University - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2013-10 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
What the finished NCT01931787 record still lists
NCT01931787 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 56-participant average among 5 other Recurrent Small Cell Lung Cancer trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Recurrent Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which 6,8-bis(benzylthio)octanoic acid is the first listed.
NCT01931787 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT01931787 about?
NCT01931787 is a clinical study titled "CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer". This pilot clinical trial studies CPI-613 (6,8-bis\[benzylthio\]octanoic acid) in treating patients with relapsed or refractory small cell lung cancer. CPI-613 may interfere with the growth of tumor cells and may be an effective treatment for small cell lung cancer.
What is the current status of trial NCT01931787?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2013-10. Estimated completion is 2015-12.
What conditions does trial NCT01931787 study?
This clinical trial studies the following conditions: Recurrent Small Cell Lung Cancer.
What interventions are being tested in trial NCT01931787?
The interventions under investigation include: 6,8-bis(benzylthio)octanoic acid (DRUG).
Who is sponsoring clinical trial NCT01931787?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01931787 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC
RECRUITING · Phase 1
-
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
COMPLETED · Phase 1
-
R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
COMPLETED · Phase 2
-
Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer
COMPLETED · Phase 2
-
Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia